Skip to main content

Accelr8 Posted Flat Q3 Revenue as R&D Spend Was Cut in Half and Losses Narrowed 40 Percent

NEW YORK (GenomeWeb News) — Accelr8 last week reported that third-quarter revenues were stable while R&D spending fell by half and losses narrowed 40 percent.
 
Total receipts for the three months ended April 30 increased to $22,700 from $19,800 year over year.
 
The company’s only revenue came from its OptiChem product line.
  
R&D spending was slashed to $247,500 from $490,000 year over year.
 
The company said net losses decreased to $477,000 from $789,000 in the year-ago period.
 
"The reduced losses reflect our planned transition from a product-engineering phase to an intensive testing phase using laboratory prototypes,” Accelr8 president David Howson said in a statement.
 
The company is testing an assay for methicillin-resistant Staphylococcus aureus infections, which are common in hospitals and be fatal.
 
Accelr8 said it had around $1.8 million in cash and cash equivalents as of April 30.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.